NH HB1772

Authorizes New Hampshire to participate in a multistate consortium conducting FDA-overseen clinical trials using ibogaine for treatment of opioid use disorder, substance use disorders, and other neurological or mental health conditions

Establishes a grant program through the Department of Health and Human Services to fund research at in-state facilities with proven neuroscience expertise, requiring matching funds from non-state sources before disbursement

Creates two dedicated funds: the Ibogaine Clinical Research Trial Fund for program administration, and the Ibogaine Intellectual Property Fund to capture revenue from any commercial rights arising from the research

Earnings from the intellectual property fund would be distributed quarterly to programs assisting veterans and other at-risk populations in New Hampshire

Appropriates $1 for fiscal year ending June 30, 2027, with the appropriation effective July 1, 2026 and remaining provisions effective 60 days after passage